| Primary |
| Cord Blood Transplant Therapy |
21.1% |
| Bone Marrow Conditioning Regimen |
17.1% |
| Large Granular Lymphocytosis |
15.8% |
| Immunosuppression |
10.5% |
| Prophylaxis Against Graft Versus Host Disease |
7.9% |
| Antifungal Prophylaxis |
5.3% |
| Product Used For Unknown Indication |
5.3% |
| Haemorrhage |
3.9% |
| Fungal Infection |
2.6% |
| Viral Infection |
2.6% |
| Acute Graft Versus Host Disease |
1.3% |
| Anti-infective Therapy |
1.3% |
| Bacterial Infection |
1.3% |
| Heart Transplant |
1.3% |
| Hodgkin's Disease |
1.3% |
| Myelodysplastic Syndrome |
1.3% |
|
| Chronic Graft Versus Host Disease |
10.5% |
| Febrile Neutropenia |
10.5% |
| No Adverse Event |
10.5% |
| Atelectasis |
5.3% |
| Death |
5.3% |
| Evans Syndrome |
5.3% |
| Haemoptysis |
5.3% |
| Human Herpesvirus 6 Infection |
5.3% |
| Hyperglycaemia |
5.3% |
| Influenza |
5.3% |
| Liver Transplant |
5.3% |
| Pulmonary Oedema |
5.3% |
| Pyrexia |
5.3% |
| Rash |
5.3% |
| Respiratory Distress |
5.3% |
| Transfusion-related Acute Lung Injury |
5.3% |
|
| Secondary |
| Stem Cell Transplant |
19.7% |
| Prophylaxis Against Graft Versus Host Disease |
15.5% |
| Acute Myeloid Leukaemia |
10.4% |
| Bone Marrow Conditioning Regimen |
7.8% |
| Immunosuppression |
7.8% |
| Renal Transplant |
4.6% |
| Acute Lymphocytic Leukaemia |
4.4% |
| Bone Marrow Transplant |
4.0% |
| Combined Immunodeficiency |
2.8% |
| Antifungal Prophylaxis |
2.7% |
| Myelodysplastic Syndrome |
2.6% |
| Infection Prophylaxis |
2.6% |
| Prophylaxis Against Transplant Rejection |
2.3% |
| Antiviral Prophylaxis |
2.0% |
| Aplastic Anaemia |
2.0% |
| Drug Use For Unknown Indication |
2.0% |
| Cord Blood Transplant Therapy |
1.8% |
| Product Used For Unknown Indication |
1.7% |
| Antibiotic Prophylaxis |
1.6% |
| Chronic Myeloid Leukaemia |
1.5% |
|
| Transplant Rejection |
11.3% |
| Pyrexia |
7.5% |
| Graft Versus Host Disease |
6.9% |
| Chronic Graft Versus Host Disease |
6.3% |
| Sepsis |
6.3% |
| Transplant Failure |
5.6% |
| Venoocclusive Disease |
5.6% |
| Acute Lymphocytic Leukaemia Recurrent |
5.0% |
| Cytomegalovirus Infection |
4.4% |
| Post Transplant Lymphoproliferative Disorder |
4.4% |
| Viral Infection |
4.4% |
| Acute Graft Versus Host Disease |
3.8% |
| Acute Graft Versus Host Disease In Skin |
3.8% |
| Epstein-barr Virus Infection |
3.8% |
| Herpes Zoster |
3.8% |
| Multi-organ Failure |
3.8% |
| Myelodysplastic Syndrome |
3.8% |
| Thrombocytopenia |
3.8% |
| Hypogammaglobulinaemia |
3.1% |
| Venoocclusive Liver Disease |
3.1% |
|
| Concomitant |
| Prophylaxis Against Graft Versus Host Disease |
21.1% |
| Product Used For Unknown Indication |
12.4% |
| Stem Cell Transplant |
11.2% |
| Bone Marrow Conditioning Regimen |
10.9% |
| Immunosuppression |
4.8% |
| Aplastic Anaemia |
4.3% |
| Acute Myeloid Leukaemia |
4.2% |
| Infection Prophylaxis |
3.8% |
| Renal Transplant |
3.0% |
| Lung Transplant |
2.9% |
| Prophylaxis |
2.9% |
| Bone Marrow Transplant |
2.8% |
| Drug Use For Unknown Indication |
2.8% |
| Immunosuppressant Drug Therapy |
2.6% |
| Precursor T-lymphoblastic Lymphoma/leukaemia |
2.4% |
| Acute Graft Versus Host Disease |
2.3% |
| Acute Lymphocytic Leukaemia |
1.7% |
| Cord Blood Transplant Therapy |
1.5% |
| Antiviral Prophylaxis |
1.3% |
| Prophylaxis Against Transplant Rejection |
1.2% |
|
| Sepsis |
11.2% |
| Drug Ineffective |
10.7% |
| Acute Graft Versus Host Disease |
7.7% |
| Cytomegalovirus Infection |
5.6% |
| Thrombotic Microangiopathy |
5.6% |
| Transplant Rejection |
5.6% |
| Graft Versus Host Disease |
5.1% |
| Osteonecrosis |
5.1% |
| Death |
4.6% |
| Burkholderia Cepacia Complex Sepsis |
4.1% |
| Chronic Graft Versus Host Disease |
3.6% |
| Epstein-barr Virus Associated Lymphoproliferative Disorder |
3.6% |
| Multi-organ Failure |
3.6% |
| Neurotoxicity |
3.6% |
| Septic Shock |
3.6% |
| Status Epilepticus |
3.6% |
| Transplant Failure |
3.6% |
| Venoocclusive Disease |
3.6% |
| Pneumonia Cytomegaloviral |
3.1% |
| Pyrexia |
3.1% |
|
